[Studies on antitumor activities of Basidiomycetes-antitumor activity of polysaccharides and sex factors].
We have already reported antitumor activities of fungal and bacterial polysaccharides on mice. In the present experiment, the influence of the sex on antitumor effects on such material  from Grifola umbellata, Coriolus versicolor Fries or Sargassum thumbergii and the immunity of mice against tumor were investigated. The growth velocities of Sarcoma 180, Ehrlich solid carcinoma, Pulmonary tumor 7423 and MF-sarcoma bearing mice both without treatment and those treated with polysaccharides were more rapid in males than in females. The regression rates in mice with the above tumors were higher in females than in males. However, a few DS Mie mice with Sarcoma 180 and A/Jax Mie mice with Ehrlich solid carcinoma regressed spontaneously. The growth velocity of Shionogi carcinoma 42 was not influenced by the sex. On other hand, both males and females which had experienced a regression of ascites tumor after the administration of polysaccharides rejected the re-implanted Ehrlich ascites carcinoma, Sarcoma 180, NF-sarcomma and Shionogi carcinoma 42. These results suggest that a strong ehancement of immune response occurs in the tumor implanted in the host animal by the administration of polysacchrides. The combination of X-ray irradiation Ehrlich ascites cells and polysacchrides strengthens the antitumor effect of NF-sarcoma and Shionogi carcinoma 42. Peritoneal exudate cells and lymphocytes were compared between the male and female mice after being treated with ATSO and P.GU-1. Such cells were present to a much greater extent in females.
D000276:Adjuvants, Immunologic; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic; D001487:Basidiomycota; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D005947:Glucose; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology; D011134:Polysaccharides / Q000276:immunology / Q000627:therapeutic use*; D012510:Sarcoma 180 / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy; D012737:Sex Factors
D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D011134:Polysaccharides; D005947:Glucose